个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
主要从事基于循证及真实世界数据的药品临床综合评价研究。作为课题负责人主持科研课题22项，包括国家自然科学基金项目4项，省部级课题3项。共发表论文200余篇，其中第一作者和通讯作者发表SCI论文32篇。获得军队科技进步二等奖1项，中华中医药学会科技进步二等奖1项，解放军总医院科技进步二等奖2项。获批中国发明专利授权2项。入选中国科协科技智库青年人才、北京市医管中心青苗人才、中国药学会医院药学优秀人才。兼任北京药理学会理事，北京药理学会合理用药与健康促进专业委员会副主任委员，中国药理学会药源性疾病学专委会常委，北京整合医学学会数智化药学管理与服务分会常委，中国药师协会区域药学服务促进工作委员会委员，中国药师协会精准药学工作委员会委员，中国药学会科学传播专业委员会委员，中国药学会医院药学专业委员会青年委员，北京医疗保险协会真实世界研究专委会委员，中国药理学会抗衰老与老年痴呆专委会委员，中国药理学会网络药理学专业委员会青年委员，北京药学会罕见病药学专委会委员，AJHP杂志中文版、医药导报、IJCP杂志中文版、中国药房杂志等期刊青年编委。
1.国家自然科学基金面上项目，开心散通过调节肠道菌群介导的BATF2-CXCL12信号异常治疗抑郁共病胃癌免疫检查点抑制剂耐药的机制研究，2026.01-2029.12
2.国家自然科学基金面上项目，CXCL12调控免疫微环境TAMs外泌体TYRO3介导胃癌PD-1/PD-L1耐药的机制研究，2023.01-2026.12
3.首都卫生发展科研专项，既往服用他汀类药物的患者自发性脑出血后是否应继续使用他汀类药物?－基于targettrialemulation 的北京医保数据库的回顾性队列研究，2024.01-2026.12
4.北京市卫健委项目，基于药品临床综合评价建立医疗机构创新药遴选体系，2025.01-2025.11
5.吴阶平基金，基于健康医疗大数据的慢性病用药临床综合评价体系的构建与实证研究，2024.11-2026.11
6.宣武医院汇智人才项目，神经系统疾病与消化道肿瘤的相互作用机制研究，2026.01-2028.12
1. Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.Alzheimer’s Research & Therapy. 2025.
2. Comparison of treatment patterns, efficacy and safety between generic and branded atorvastatin users in China: a multicenter, retrospective propensity score-matched cohort study. Lipids Health Dis. 2025.
3. Updating the potentially inappropriate medication (PIM)-China criteria for 2024: a Delphi consensus study for improved medication safety in older adults. Int J Clin Pharm. 2025.
4. Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records. Front Pharmacol. 2025.
5. Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy. Discov Oncol. 2025.
6.Single-cell RNA sequencing reveals the ameliorative effects of Kai-Xin-San on depression via regulating neuroplasticity and inflammation in the hypothalamus of rats. Neuroscience. 2025.
7. Research progress in the construction and application of immunotherapy resistance models. Cancer Immunol Immunother. 2025.
8. Therapeutic equivalence and switching between biosimilar and reference insulins: A systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2025.
9. Neurobrucellosis: laboratory features, clinical characteristics, antibiotic treatment, and clinical outcomes of 21 patients. BMC Infectious Diseases. 2024.
10. Effects of regulating gut microbiota by electroacupuncture in the chronic unpredictable mild stress rat model.Neuroscience. 2024.
11. Impact and implications of national centralized drug procurement in China. International Journal of Clinical Pharmacy. 2024.
12. Interaction between Chinese medicine and digoxin: Clinical and research update. Front Pharmacol. 2023.
13. Traditional Chinese medicine decoctions and Chinese patent medicines for the treatment of depression: Efficacies and mechanisms. J Ethnopharmacol. 2023.
14. Epithelial-mesenchymal transition-related long noncoding RNAs in gastric carcinoma. Front Mol Biosci. 2022.
15.miR-1273h-5p suppresses the penetration and pervasion of gastric cancer cells via suppressing CXCL12 expression. Open medicine. 2022.
16.Anti-depressive effects of Kai-Xin-San on lipid metabolism in depressed Patients and CUMS rats using metabolomic analysis. J Ethnopharmacol. 2020.
17.LncRNA COL1A1-014 is involved in the progression of gastric cancer via regulating CXCL12-CXCR4 axis. Gastric Cancer. 2020.
文件上传中...
